ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SRTA / insiders
AUNA (45) SBC (72) STLN (38) AHCO (33) ⌘ Pro Terminal →

Strata Critical Medical Inc. (Class A) (SRTA) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$4.28 -3.60% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.24

Strata Critical Medical Inc. (Class A) (SRTA) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $392.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SRTA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SRTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Strata Critical Medical Inc. (Class A) (NASDAQ: SRTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $4.28 (-3.60% 1D, market cap $392.8M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, SRTA ranks #624 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SRTA compare to AUNA and SBC in the Health Care sector?
▼

Within the Health Care sector (Medical/Nursing Services), SRTA carries a Roarable E (34/100 RQD), trailing P/E of 10.2x, gross margin of 20.9%, and ROIC of -7.1%. By comparison, AUNA (Auna SA (Class A)) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $333.8M) and SBC (SBC Medical Group Holdings Incorporated) posts a B grade (72/100 RQD, P/E 11.5x, ROIC 63.1%, cap $542.5M). Among the 5-stock peer group, SRTA leads on earnings multiple (10.2x) while SBC leads on capital efficiency (63.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SRTA?
▼

Per SRTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001779128), Strata Critical Medical Inc. (Class A) generated $197.1M in revenue (+34.3% YoY), $41.3M in net income, and -$58.5M in free cash flow against $325.5M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.24 (-0.84%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (5)Whales (3)SEC (16)Macro (3)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-10.7% Base Target
$7 Bull$4 Base$3 Bear
📬 FREE SRTA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SRTA)Realized 20D OHLCV Swing Band: ±7.7%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY SRTA SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (47% of score)

Altman Z-Score 5.58 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+7/20 pts (21% of score)

SEC Form 4 / 13F Thermometer: 35% Net Buy • Dilution Drag (+1.36% YoY Shares)

▼ #1 Drag / Risk Factor: Macro Regime Fit4/20 pts (-16 pt drag)

Macro rate sensitivity & RSI-14 (40.4) create a -16 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$4.45+5.4% Next Q
Q2 (-2Q)
39
Grade E$4.69+0.6% Next Q
Q3 (-1Q)
37
Grade E$4.72-9.3% Next Q
Current
34
Grade E$4.28-8.7% Hist 90D α
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SRTA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SRTA currently carries a cautious 34/100 (E) rating due to Macro Regime Fit (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.04) and Max Pain ($4.49) forces dealer call-delta covering toward $6.83.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SRTA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SRTA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

SRTA Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SRTA)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SRTA. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SRTA)

  • ✓Walkthrough of SRTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SRTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -12.65%▼ DESCENDING CHANNEL
2026-11-03O $4.75H $4.75L $4.28C $4.28VOL 1.11M
RES: $6.19SUP: $4.06SMA50: $5.04SMA200: $5.09
$6.66$6.00$5.33$4.67$4.00RES $6.19SUP $4.06$4.282026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SRTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SRTA Butterfly Map → + Track SRTA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
-0.8%/yr Implied 5Y Growth

vs. +34.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SRTA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SRTA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SRTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SRTA)

Health Care Rank #624 of 1015 ⚔️ AUNA vs SRTA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SRTA vs. AUNA, SBC, STLN, AHCO)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Strata Critical Medical Inc. (Class A) (SRTA) ranks #624 by composite RQD confidence (34/100, grade E) and #475 by equity capitalization ($392.8M). Within this direct 5-issuer industry benchmark cohort, SRTA leads on earnings valuation at 10.2x trailing P/E, while SBC leads on capital efficiency and profitability with 63.1% ROIC and 73.3% gross margin. SBC currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with SRTA at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SRTA ACTIVE
Strata Critical Medical Inc. (Class A)
E 34/100 10.2x 20.9% -7.1% -3.60% $392.8M Benchmark Subject
AUNA
Auna SA (Class A)
D 45/100 — — — -0.22% $333.8M /auna-vs-srta →
SBC
SBC Medical Group Holdings Incorporated
B 72/100 11.5x 73.3% 63.1% +0.66% $542.5M /sbc-vs-srta →
STLN
Starling Oncology Inc.
D- 38/100 — — -35.0% -4.29% $665.5M /stln-vs-srta →
AHCO
AdaptHealth Corp.
E 33/100 — 18.8% 2.2% +1.72% $792.2M /ahco-vs-srta →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001779128 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Strata Critical Medical Inc. (Class A) (SRTA) reported GAAP revenue of $197.1M (+34.3% vs. FY2024 revenue of $146.8M , and -12.5% cumulative change since FY2023) , GAAP net income of $41.3M, operating cash flow of -$48.9M, and free cash flow of -$58.5M (-75.3% YoY). On the balance sheet, SRTA closed FY2025 with $325.5M in total assets against $0 in total debt (Altman Z-Score: 5.58, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $197.1M $41.3M -$48.9M -$58.5M $325.5M —
FY2024 (FY) 2024-12-31 $146.8M -$27.3M -$2.5M -$33.4M $256.7M —
FY2023 (FY) 2023-12-31 $225.2M -$56.1M -$32.3M -$32.3M — —

3. SRTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SRTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Strata Critical Medical Inc. (Class A) (NASDAQ: SRTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $4.28 (-3.60% 1D, market cap $392.8M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, SRTA ranks #624 in composite RQD confidence.

How does SRTA compare to AUNA and SBC in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), SRTA carries a Roarable E (34/100 RQD), trailing P/E of 10.2x, gross margin of 20.9%, and ROIC of -7.1%. By comparison, AUNA (Auna SA (Class A)) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $333.8M) and SBC (SBC Medical Group Holdings Incorporated) posts a B grade (72/100 RQD, P/E 11.5x, ROIC 63.1%, cap $542.5M). Among the 5-stock peer group, SRTA leads on earnings multiple (10.2x) while SBC leads on capital efficiency (63.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SRTA?

Per SRTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001779128), Strata Critical Medical Inc. (Class A) generated $197.1M in revenue (+34.3% YoY), $41.3M in net income, and -$58.5M in free cash flow against $325.5M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SRTA trading relative to its 50-day, 200-day, and 52-week technical levels?

SRTA last traded at $4.28 (-3.60% on volume of 2,260,085 shares), positioning the stock -15.08% below its 50-day simple moving average ($5.04) and -15.91% below its 200-day simple moving average ($5.09). Across its 52-week range of $3.95 to $6.50, SRTA sits at the 12.9% percentile with a 14-day RSI of 40.4 (NEUTRAL RANGE) and an implied next-earnings move of ±7.7% ($3.95 to $4.61).

Direct Sub-Reports: SRTA RQD Cockpit SRTA 12M Forecast SRTA Earnings & Move SRTA Dividends & DRIP SRTA Insiders & 13F SRTA Whale Options SRTA Profit Sankey SRTA News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

SRTA — Strata Critical Medical Inc. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Strata Critical Medical Inc. (Class A) (SRTA) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.28 (-3.60% 1D, market capitalization $392.8M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -7.1%, gross margin of 20.9%, operating margin of -11.3%, and free cash flow yield of -13.92%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (3/20) + Forensic Balance Sheet (16/20): Incorporates a 1.00x equity beta, Altman Z-Score of 5.58, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Strata Critical Medical Inc. (Class A) is a NASDAQ-listed issuer classified in the Health Care sector and the Medical/Nursing Services industry. Reported revenue across fiscal years 2023 through 2025 is shown in the financial trend below.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Strata Critical Medical Inc. (Class A) (SRTA) reported $197.1M in annual revenue (up from $146.8M in FY2024, +34.3% YoY) and $41.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($225.2M revenue, -$56.1M net income) through FY2025, SRTA scaled operating cash flow to -$48.9M and free cash flow to -$58.5M, backed by $325.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of -13.92% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.95 – $6.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 10.2x trailing P/E against -11.3% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Investors should watch the scheduled Q3 release referenced in the news feed for any disclosure of drivers, which the current data does not provide.

  • Key Question #1: Can SRTA sustain or expand its -11.3% operating margin and -7.1% ROIC against Medical/Nursing Services peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $197.1M and free cash flow of -$58.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SRTA's 8.6x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SRTA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Strata Critical Medical Inc. (Class A) (SRTA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SRTA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SRTA Bull vs. Bear Conversation Board — What's Your Call at $4.28?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SRTA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SRTA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $5.55 (+25.0%)
📌 Pinned Debate

Low forward P/E of 8.6 combined with a 16/20 forensic balance sheet score (Altman Z 5.58, Debt/Equity 0.5) suggests the stock is priced

Don't sleep on SRTA's setup in Health Care. Low forward P/E of 8.6 combined with a 16/20 forensic balance sheet score (Altman Z 5.58, Debt/Equity 0.5) suggests the stock is priced cheaply relative to its solvency profile.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (34/100) backs up the fundamental quality.

EarningsSniper 🐂 BULL

@MeanReversion_88 Shorting a 3/20 institutional whale-flow stock at $4.44 is dangerous when funds are rotating into Health Care.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $3.37 (-24.1%)
Spot @ $4.44

Negative operating income in every reported period, FCF yield of -13.92%, and ROIC of -7.1% leave the cash engine scoring only 5/20.

Fading this rally in SRTA at $4.44. Negative operating income in every reported period, FCF yield of -13.92%, and ROIC of -7.1% leave the cash engine scoring only 5/20.. With a beta of 1.0 and the stock sitting at $4.44 (52-wk range $3.95–$6.50), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%